Effects of a 50+ Toothpaste on Halitosis and Oral Comfort in Healthy Adults

NCT07780474 · tracked via the Priya Life Science Italy tracker

Sponsor

University of Pavia

Phase

Not applicable

Started

2026-10-01

Last updated

2026-08-21

Condition(s) studied

Oral Malodor (Halitosis)Oral Dryness

Investigational drug(s) / intervention(s)

50+ ToothpasteStandard Fluoride Toothpaste

50+ Toothpaste: A toothpaste formulated for adults aged 50 years and older. Participants will use approximately 2 cm of toothpaste to brush their teeth for 2 minutes, twice daily, for 14 consecutive days. The product will be supplied in neutral, coded packaging to maintain masking. Participants will not use other toothpastes, mouthwashes, tongue-cleaning procedures, or products intended for halitosis or dry mouth during the treatment period.

Standard Fluoride Toothpaste: A commercially available fluoride toothpaste intended for routine oral hygiene, without specific claims for halitosis or dry mouth and without ingredients specifically intended to neutralize volatile sulfur compounds. Participants will use approximately 2 cm of toothpaste to brush their teeth for 2 minutes, twice daily, for 14 consecutive days. The product will be supplied in neutral, coded packaging, and the same oral hygiene restrictions used for the 50+ toothpaste will apply.

Study summary

The goal of this clinical trial is to compare a toothpaste designed for adults aged 50 years and older with a standard toothpaste in orally healthy adults. The main question is whether the 50+ toothpaste reduces bad breath more than the standard toothpaste after 14 days of twice-daily use. The study will also assess tongue coating, dry mouth symptoms, saliva production, oral comfort, oral health-related quality of life, taste, acceptability, and unwanted effects.

About 30 adults aged 18 to 65 years will take part. Each participant will use both toothpastes for 14 days each, in a randomly assigned order, with a 14-day break between the two treatment periods. Neither the participants nor the examiner performing the assessments will know which toothpaste is being used during each period.

At the study visits, bad breath will be measured using a device that detects volatile sulfur compounds in the mouth. Participants will also undergo an examination of the tongue, provide saliva samples, and complete questionnaires. Before each assessment visit, participants will be asked not to perform oral hygiene for 24 hours and to avoid food, drinks other than water, smoking, chewing gum, and oral care products for 3 to 4 hours.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Age between 18 and 65 years. * Male or female. * Orally healthy according to clinical examination, with no active oral condition that could interfere with study outcomes. * At least 20 natural teeth. * No active periodontitis. * No clinically relevant untreated cavitated caries. * No acute oral mucosal disease. * Any existing systemic condition must be stable, controlled, and considered unlikely to interfere with the study outcomes. * Willingness to use only the oral care products provided during each treatment period. * Willingness to refrain from oral hygiene procedures for 24 hours before each assessment visit. * Willingness to refrain from food, beverages other than water, smoking, chewing gum, candies, oral sprays, mouthwashes, and oral hygiene procedures for 3 to 4 hours before each assessment. * Ability to understand the study objectives and procedures. * Provision of written informed consent. Exclusion Criteria: * Active oral or dental disease that could interfere with the study outcomes. Active periodontitis. * Periodontal probing depths greater than 3 mm at multiple sites, according to clinical judgment. * Clinically relevant generalized gingival bleeding. * Clinically relevant untreated cavitated caries. * Oral candidiasis. * Oral ulceration, stomatitis, symptomatic oral mucosal lesions, or acute oral infection. * Clinical signs of severe xerostomia or pathological hyposalivation. * Fewer than 20 natural teeth. * Acute systemic disease or uncontrolled chronic systemic disease. Uncontrolled diabetes mellitus. * Active autoimmune or systemic inflammatory disease. * Gastrointestinal, respiratory, otorhinolaryngological, or metabolic conditions associated with clinically significant extraoral halitosis. * Use of systemic antibiotics within 4 weeks before enrollment. * Habitual use of antiseptic mouthwashes, anti-halitosis products, or dry-mouth products within 2 weeks before enrollment. * Use of medications with a strong xerostomic effect that, in the investigator's judgment, could interfere with study outcomes. * Smoking more than 10 cigarettes per day. * Inability to refrain from smoking for 3 to 4 hours before assessment visits. * Pregnancy or breastfeeding. * Known or suspected allergy to any component of the study products. * Professional dental cleaning or invasive dental procedures within 2 weeks before enrollment. * Inability or unwillingness to comply with the study procedures. * Participation in another clinical study within 4 weeks before enrollment.

Primary outcome measure(s)

Change From Baseline in Oral Volatile Sulfur Compound Concentration After 14 Days — Baseline (T0), after 7 days of treatment (T1), and after 14 days of treatment (T2) in each treatment period
Oral volatile sulfur compound concentration will be measured using a Halimeter Plus and expressed in parts per billion (ppb). At each assessment, three valid consecutive measurements will be obtained, and their mean will be used for analysis. For each treatment period, change from baseline will be calculated as the value after 14 days minus the baseline value. Lower values and greater reductions indicate improvement in oral malodor. The primary comparison will assess the within-participant difference in change between the 50+ toothpaste and the standard fluoride toothpaste.

Trial sites (1)

Facility	City	Region	Status
Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia	Pavia	Lombardy

More University of Pavia trials in Italy

Effects of Blood Flow Restriction Combined With Electrostimulation After Knee Arthroplasty Active, not recruiting

Efficacy of Transverse Maxillary Expansion With AMCOP Preformed Appliances Enrolling by invitation

Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging Starting soon

Comparison of Digital Analysis and Artificial Intelligence for Cephalometric Tracing Recruiting

Adjunctive Periodontal Treatment With Coenzyme Q10 in Association With Probiotics for Pregnant Women Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07780474 on ClinicalTrials.gov ↗ ← All trials in Italy